Regulus Therapeutics Inc. - stock earnings
RGLS Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q3 | -7.8 million USD | ? USD |
| 2023Q2 | -7.0 million USD | ? USD |
| 2023Q1 | -7.1 million USD | ? USD |
| 2022Q4 | -6.8 million USD | ? USD |
| 2022Q3 | -7.5 million USD | ? USD |
| 2022Q2 | -7.3 million USD | ? USD |
| 2022Q1 | -6.7 million USD | ? USD |
| 2021Q4 | -7.1 million USD | 10 USD |
| 2021Q3 | -8.6 million USD | 2504 USD |
| 2021Q2 | -6.0 million USD | 2488 USD |
| 2021Q1 | -6.0 million USD | 5.0 million USD |
| 2020Q4 | -1.3 million USD | 5.0 million USD |
| 2020Q3 | -1.5 million USD | 5.0 million USD |
| 2020Q2 | -6.9 million USD | ? USD |
| 2020Q1 | -5.9 million USD | 6000 USD |
| 2019Q4 | -4.9 million USD | 18000 USD |
| 2019Q3 | -5.4 million USD | 18000 USD |
| 2019Q2 | -5.0 million USD | 18000 USD |
| 2019Q1 | -3.3 million USD | 6.8 million USD |
| 2018Q4 | -8.6 million USD | 18000 USD |
| 2018Q3 | -10.3 million USD | 18000 USD |
| 2018Q2 | -13.8 million USD | 18000 USD |
| 2018Q1 | -16.0 million USD | 18000 USD |
| 2017Q4 | -14.4 million USD | 18000 USD |
| 2017Q3 | -15.8 million USD | 18000 USD |
| 2017Q2 | -21.6 million USD | 18000 USD |
| 2017Q1 | -20.0 million USD | 18000 USD |
| 2016Q4 | -20.0 million USD | 18000 USD |
| 2016Q3 | -19.5 million USD | 204000 USD |
| 2016Q2 | -21.1 million USD | 483000 USD |
| 2016Q1 | -21.2 million USD | 489000 USD |
| 2015Q4 | -7.2 million USD | 10.9 million USD |
| 2015Q3 | -13.0 million USD | 1.9 million USD |
| 2015Q2 | -21.0 million USD | 3.8 million USD |
| 2015Q1 | -14.5 million USD | 4.2 million USD |
| 2014Q4 | -22.2 million USD | 4.2 million USD |
| 2014Q3 | -9.8 million USD | 1.1 million USD |
| 2014Q2 | -12.0 million USD | 736000 USD |
| 2014Q1 | -12.7 million USD | 1.6 million USD |
| 2013Q4 | -1.9 million USD | 5.5 million USD |
| 2013Q3 | -2.2 million USD | 6.1 million USD |
| 2013Q2 | -7.3 million USD | 4.8 million USD |
| 2013Q1 | -7.2 million USD | 3.2 million USD |
| 2012Q4 | -6.9 million USD | 3.2 million USD |
| 2012Q3 | -5.7 million USD | 2.8 million USD |
| 2012Q2 | -2.6 million USD | 3.3 million USD |
| 2012Q1 | -2.2 million USD | 3.3 million USD |
| 2011Q4 | -2.0 million USD | 3.4 million USD |
| 2011Q3 | -1.0 million USD | 3.8 million USD |
| 2011Q2 | ? USD | 6.6 million USD |
| 2010Q4 | ? USD | 8.6 million USD |
RGLS Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -28.8 million USD | ? USD |
| 2022 | -28.3 million USD | ? USD |
| 2021 | -27.8 million USD | 10022 USD |
| 2020 | -15.3 million USD | 10.0 million USD |
| 2019 | -18.6 million USD | 6.8 million USD |
| 2018 | -48.7 million USD | 72000 USD |
| 2017 | -71.9 million USD | 72000 USD |
| 2016 | -81.8 million USD | 1.2 million USD |
| 2015 | -55.7 million USD | 20.8 million USD |
| 2014 | -56.7 million USD | 7.7 million USD |
| 2013 | -18.7 million USD | 19.6 million USD |
| 2012 | -17.4 million USD | 12.7 million USD |
| 2011 | -7.6 million USD | 13.8 million USD |
| 2010 | -15.6 million USD | 8.6 million USD |
RGLS
Price: $2.50
52 week price:
Earnings Per Share: -1.58 USD
P/E Ratio: -0.89
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 68300
Ebitda: -14.7 millionMarket Capitalization: 169.6 million